Stockscreener 앱 받기
2.45
4.70%
0.11
시간 외 거래:
2.40
-0.05
-2.04%
Cellectar Biosciences Inc 주식(CLRB)의 최신 뉴스
Number of shareholders of Cellectar Biosciences, Inc. – MUN:NV40 - TradingView
Cellectar Biosciences (CLRB) director Andrew Gu submits initial Form 3 ownership filing - Stock Titan
Cellectar Biosciences (CLRB) Declines 3.09% as Stock Tests Support Near $2.38Swing Entry Signals - newsline.com
Janus Henderson Group holds 9.99% of Cellectar Biosciences (CLRB) - Stock Titan
Cellectar Biosciences (CLRB) Q1 2026 Earnings: Narrower Loss Beats Estimates as Pipeline Progress ContinuesProfit Announcement - newsline.com
[EFFECT] Cellectar Biosciences, Inc. SEC Filing - Stock Titan
Cellectar Biosciences (CLRB) registers 51.998M shares for resale; board seat named - Stock Titan
Cellectar plans phase 3 trial for WM treatment after BTKi - Investing.com UK
Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenström Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting - Investing News Network
Cellectar plans phase 3 trial for WM treatment after BTKi By Investing.com - Investing.com South Africa
Cellectar Biosciences Q1 2026 earnings preview - MSN
Cellectar (NASDAQ: CLRB) details 51.9M-share resale tied to May 2026 financing - Stock Titan
Cellectar Biosciences (CLRB) upgraded to buy: Here's what you should know - MSN
Large warrant exercise and equity plan votes ahead for Cellectar (NASDAQ: CLRB) - Stock Titan
Cellectar Biosciences (CLRB) Edges Higher: Support Levels Tested as Biotech Sector Shows Mixed SignalsFundamental Weighted - newsline.com
Cellectar Biosciences Edges Higher, Finding Support Near $3.04Growth Stock Picks - The Legal Advocate
Cellectar Biosciences Bets on Iopofosine Breakthrough - TipRanks
Cellectar Biosciences Files for Secondary Offering of Common Shares - Moomoo
Cellectar Biosciences Announces Board Changes and New Director - The Globe and Mail
Cellectar (NASDAQ: CLRB) S-1 details 51.2M-share resale and major warrant overhang - Stock Titan
Cellectar Biosciences (NASDAQ: CLRB) seeks approval for warrants and plan increase - Stock Titan
Cellectar Biosciences appoints Andrew Gu to board; Stefan D. Loren to step down, join as consultant - TradingView
Cellectar (NASDAQ: CLRB) reshapes board with Loren exit and Andrew Gu appointment - Stock Titan
Cellectar Biosciences, Inc. Announces Board Changes - marketscreener.com
User | dailytimesleader.comCellectar Biosciences, Inc.Common Stock (Nasdaq:CLRB) Stock Quote - FinancialContent
Cellectar (CLRB) phase 2b data shows durable responses in Waldenström macroglobulinemia - MSN
CLRB Assumed by Ladenburg Thalmann -- Rating Set to Buy - GuruFocus
Maxim Group Maintains Cellectar BioSciences(CLRB.US) With Buy Rating, Maintains Target Price $10 - Moomoo
Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2026 Earnings Call Transcript - Insider Monkey
Cellectar Biosciences Reports Positive Phase 2b Data for Iopofosine I 131 in Waldenström Macroglobulinemia and Secures $140M Financing for Phase 3 Trial and FDA Filing - Minichart
Cellectar Biosciences, Inc.Common Stock (NQ: CLRB - FinancialContent
What's Going With Cellectar Biosciences Stock On Wednesday? - MSN
Cellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid Financial Challenges - GuruFocus
Cellectar Biosciences Signals Pivotal Turn in Earnings Call - TipRanks
Cellectar Biosciences Q1 2026 Earnings Call Transcript - MarketBeat
Cellectar Biosciences (CLRB) Reports Positive Phase IIb Results and Plans FDA Filing - GuruFocus
Cellectar Biosciences, Inc. Q1 2026 Earnings Call Summary - Yahoo Finance
Cellectar Biosciences, Inc. Q1 2026 Financial Report, Forward-Looking Statements, and SEC Filings - Minichart
Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates - Investing News Network
Cellectar plans phase III start in late Q4 2026 as it outlines potential WM approval in the second half of 2027 - MSN
Earnings call transcript: Cellectar Biosciences Q1 2026 shows progress - Investing.com UK
Is Cellectar Biosciences (CLRB) Attractively Valued After Q1 202 - GuruFocus
Cellectar Biosciences Releases Q1 2026 Financial Results - AlphaStreet
Cellectar Biosciences Q1 2026: Loss Narrows 29.6% to -$1.33/Share - AlphaStreet
Earnings call transcript: Cellectar Biosciences Q1 2026 shows progress By Investing.com - Investing.com Nigeria
CLRB: Strong clinical results and $140M financing drive late-stage execution and regulatory momentum - TradingView
1.27%
1.43%
자본화:
|
볼륨(24시간):